A Phase II, randomized, double-blind, placebo-controlled trial of indoximod in combination with durvalumab, along with gemcitabine/ABRAXANE (nab-paclitaxel) and durvalumab with gemcitabine/ABRAXANE versus gemcitabine/ABRAXANE for patients with metastatic pancreatic cancer.
Phase of Trial: Phase II
Latest Information Update: 03 May 2018
At a glance
- Drugs Durvalumab (Primary) ; Indoximod (Primary) ; Gemcitabine; Paclitaxel
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Acronyms Indigo201
- Sponsors New Links Genetics Corporation
- 03 May 2018 According to a NewLink Genetics Corporation media release, data from this trial will be presented at the ASCO Annual Meeting, June 2018
- 02 Nov 2017 According to a NewLink Genetics Corporation media release, the company expects to initiate this trial in the first half of 2018.
- 28 Sep 2017 New trial record